Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

  • Discontinued
  • GID-TA10070
Sunesis was unable to make a submission to NICE ahead of the marketing authorisation for Vosaroxin based on resource constraints and intends to follow up with a full submission in a timely manner. NICE therefore rescheduled this appraisal.